Related Experiment Video
Updated: Aug 8, 2026
Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments
Published on: October 15, 2016
Intracellular expression of the anti-erbB-2 sFv N29 fails to accomplish efficient target modulation
J E Grim1, G P Siegal, R D Alvarez
1Gene Therapy Program, University of Alabama at Birmingham, Birmingham, Alabama, 35294, USA.
Abstract:
The use of intracellular single chain antibodies has recently emerged as a highly efficient method of down-regulating or ablating protein expression. In this regard, we have demonstrated that a single chain antibody directed against the extracellular domain of the erbB-2 molecule causes a specific toxicity in erbB-2 positive tumor types. To further investigate the mechanism of this effect, we developed a second anti-erbB-2 sFv predicted to recognize an alternate extracellular epitope of the erbB-2 molecule. When produced as a secreted protein from the erbB-2 negative COS-1 cell line, this sFv binds specifically to erbB-2 positive cells, indicating that cellular machinery is able to produce a properly folded and functional sFv protein. However, by several assays, this sFv was shown to be unable to retain the erbB-2 protein within the ER. These negative results have implications for the evaluation and utilization of sFv knockout strategies in experimental contexts.
Insights
Researchers explored using single chain antibodies (sFv) to target the erbB-2 protein. A new sFv antibody showed specific binding but could not retain erbB-2 in the ER, impacting knockout strategies.
Area of Science:
- Molecular Biology
- Immunology
- Oncology
Background:
- Single chain antibodies (sFv) are effective tools for protein expression down-regulation.
- Previous work showed an anti-erbB-2 sFv induces specific toxicity in erbB-2 positive tumors.
Purpose of the Study:
- To investigate the mechanism of anti-erbB-2 sFv-mediated tumor toxicity.
- To develop and characterize a novel anti-erbB-2 sFv targeting a different epitope.
- To assess the functional capability of the new sFv in retaining erbB-2 within the endoplasmic reticulum (ER).
Main Methods:
- Development of a second single chain variable fragment (sFv) antibody against erbB-2.
- Production of the sFv as a secreted protein in COS-1 cells.
- Assessment of sFv binding specificity to erbB-2 positive cells.
- Evaluation of sFv's ability to retain erbB-2 protein within the ER using various assays.
Main Results:
- The newly developed anti-erbB-2 sFv was successfully produced as a functional, secreted protein.
- This sFv demonstrated specific binding to erbB-2 positive cells.
- Crucially, the sFv failed to retain erbB-2 protein within the ER across multiple experimental assays.
Conclusions:
- The study highlights the complexity of sFv knockout strategies.
- The inability of the sFv to retain erbB-2 in the ER suggests limitations for certain protein ablation mechanisms.
- Findings impact the design and interpretation of experiments utilizing sFv for protein knockdown.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...